Stock DNA
Pharmaceuticals & Biotechnology
CNY 12,506 Million (Large Cap)
16.00
NA
4.08%
-0.19
25.60%
4.08
Revenue and Profits:
Net Sales:
1,007 Million
(Quarterly Results - Mar 2025)
Net Profit:
217 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.41%
0%
-3.41%
6 Months
-10.65%
0%
-10.65%
1 Year
-2.17%
0%
-2.17%
2 Years
28.84%
0%
28.84%
3 Years
58.55%
0%
58.55%
4 Years
72.83%
0%
72.83%
5 Years
136.8%
0%
136.8%
Henan Lingrui Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.51%
EBIT Growth (5y)
19.03%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
1.12
Tax Ratio
12.98%
Dividend Payout Ratio
70.26%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
29.45%
ROE (avg)
18.32%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
4.08
EV to EBIT
15.26
EV to EBITDA
13.74
EV to Capital Employed
4.79
EV to Sales
3.25
PEG Ratio
0.72
Dividend Yield
4.08%
ROCE (Latest)
31.41%
ROE (Latest)
25.60%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY
Mar'25
Mar'24
Change(%)
Net Sales
1,006.70
895.80
12.38%
Operating Profit (PBDIT) excl Other Income
235.30
221.40
6.28%
Interest
0.50
0.10
400.00%
Exceptional Items
-0.40
0.70
-157.14%
Consolidate Net Profit
216.70
190.30
13.87%
Operating Profit Margin (Excl OI)
233.80%
225.80%
0.80%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2025 is 12.38% vs 15.19% in Mar 2024
Consolidated Net Profit
YoY Growth in quarter ended Mar 2025 is 13.87% vs 31.97% in Mar 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
3,455.50
3,265.10
5.83%
Operating Profit (PBDIT) excl Other Income
798.90
669.60
19.31%
Interest
0.70
0.60
16.67%
Exceptional Items
0.30
-1.60
118.75%
Consolidate Net Profit
722.60
568.10
27.20%
Operating Profit Margin (Excl OI)
209.10%
179.80%
2.93%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 5.83% vs 10.27% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 27.20% vs 22.09% in Dec 2023
About Henan Lingrui Pharmaceutical Co., Ltd. 
Henan Lingrui Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






